First-in-class treatment to delay onset of type 1 diabetes

Human medicines European public assessment report (EPAR): Teizeild, teplizumab, Status: Opinion

Human medicines European public assessment report (EPAR): Dafiro, amlodipine,valsartan, Date of authorisation: 15/01/2007, Revision: 34, Status: Authorised

HMA/EMA multi-stakeholder workshop on artificial intelligence (AI), Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 November 2025, 13:00 (CET) to 21 November 2025, 12:50 (CET)

Human medicines European public assessment report (EPAR): Copalia, amlodipine,valsartan, Date of authorisation: 15/01/2007, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Exforge, amlodipine,valsartan, Date of authorisation: 16/01/2007, Revision: 35, Status: Authorised

Risperidone

Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 45, Status: Authorised

Search tips

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 12, Status: Authorised